Table 1 Clinical characteristics
From: Severity scores for status epilepticus in the ICU: systemic illness also matters
Participant characteristic | N = 166 |
|---|---|
Age, years, mean ± SD | 62 ± 15 |
Female, n (%) | 83 (50.0) |
Etiology, n (%) | |
 Acute symptomatica | 114 (68.7) |
 Remote symptomatic | 33 (19.9) |
 Progressive symptomatic | 10 (6.0) |
 SE in defined electroclinical syndromes | 1 (0.6) |
 Unknown | 8 (4.8) |
Seizure history, n (%) | 49 (29.5) |
SE diagnosed in ICU, n (%) | 137 (82.5) |
SE diagnosed outside ICU, n (%) | 29 (17.5) |
Type of SE, n (%) | |
 With prominent motor symptoms | 96 (57.8) |
  Convulsive SE | 63 (38.0) |
  Myoclonic SE | 11 (6.6) |
  Focal motor | 22 (13.2) |
 Without prominent motor symptoms | 70 (42.1) |
  Generalized NCSE with stupor or coma | 30 (18.0) |
  Focal NCSE without coma | 40 (24.1) |
Refractory SE, n (%) | 99 (59.6) |
Super-refractory SE, n (%) | 19 (11.4) |
Baseline scores, median (IQR) | |
 GCS | 6 (3–9) |
 CCI | 4 (3–6) |
 STESS | 3 (2–4) |
 EMSE-EACE | 59 (35–84) |
 INCNS | 16 (12–21) |
 APACHE-2 | 22 (18–26) |
 SAPS-2 | 56 (43–66) |
 SOFA | 8 (5–11) |
Treatments | |
 Number of antiseizure drugs, median (IQR) | 3 (2–4) |
 Use of any CIVAD, n (%) | 58 (34.9) |
 Use of ≥ 2 CIVADS, n (%) | 16 (9.6) |
 Mechanical ventilation, n (%) | 118 (71.1) |
 Use of vasopressors, n (%) | 73 (44.0) |